Nevro (NYSE:NVRO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO) in a research report sent to investors on Wednesday. The firm issued a hold rating on the medical equipment provider’s stock.

Several other analysts have also weighed in on NVRO. Citigroup lowered their target price on shares of Nevro from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. Morgan Stanley lowered shares of Nevro from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $9.00 to $4.00 in a research report on Monday, December 2nd. Truist Financial lowered their price target on shares of Nevro from $7.00 to $4.70 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Canaccord Genuity Group upped their price target on shares of Nevro from $4.00 to $5.85 and gave the stock a “hold” rating in a research report on Friday, February 7th. Finally, Wells Fargo & Company lowered their price target on shares of Nevro from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Nevro has a consensus rating of “Hold” and a consensus price target of $6.43.

Nevro Price Performance

NVRO stock opened at $5.73 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 5.02 and a quick ratio of 3.76. Nevro has a 1-year low of $3.16 and a 1-year high of $15.98. The firm has a fifty day moving average price of $4.66 and a two-hundred day moving average price of $4.92. The firm has a market cap of $214.71 million, a price-to-earnings ratio of -3.03 and a beta of 0.91.

Institutional Investors Weigh In On Nevro

Several institutional investors have recently bought and sold shares of NVRO. Amundi acquired a new stake in Nevro in the fourth quarter worth about $30,000. Oxford Asset Management LLP acquired a new stake in Nevro in the fourth quarter worth about $39,000. Corton Capital Inc. acquired a new stake in Nevro in the fourth quarter worth about $43,000. Headlands Technologies LLC acquired a new stake in Nevro in the 4th quarter valued at about $45,000. Finally, Ieq Capital LLC acquired a new stake in Nevro in the 4th quarter valued at about $46,000. Institutional investors and hedge funds own 95.52% of the company’s stock.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.